Biogen's Neuroscience Strategy Includes De-Risking The Pipeline
Executive Summary
Biogen is laser-focused on leading neuroscience, but management also talked about ways to balance the high-risk nature of competing in the challenging therapeutic area.
You may also be interested in...
Takeda Catches Rising Tide Of Antisense Neuroscience R&D
Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between the US's Wave Life Sciences and Japan's Takeda, that could include co-commercialization by the biotech in the US.
Biopharma Quarterly Deal-Making Statistics, Q2 2017
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.
Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
Q2 reporting is on a roll as GSK unveils a major shake-up under new CEO Walmsley; the prospect of a simplified route to approval may have helped Neuroderm secure Mitsubishi take-out; biosimilar developments include Celltrion Healthcare's IPO and Merck & Co's launch of Renflexis in the US; clinical trial updates were reported for Keytruda, Ironwood's GERD candidate and Vertex's next generation of cystic fibrosis candidates. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.